2021 年第三季度报告 一、 主要财务数据 主要会计数据和财务指标 (一)主要会计数据和财务指标 证券代码：688067 证券简称：爱威科技 爱威科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 55,279,669.95 | 19.66 | 152,588,122.6 ...

证券代码：688067 证券简称：爱威科技 公告编号：2021-017 爱威科技股份有限公司 关于参加 2021 年湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步强化与投资者的互动交流，使广大投资者能更深入全面地了解公 司情况，爱威科技股份有限公司（以下简称"公司"）将参加由中国证券监督管 理委员会湖南监管局举办、湖南省上市公司协会与深圳市全景网络有限公司协 办的"2021 年湖南辖区上市公司投资者网上集体接待日"活动，现将有关事项 公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台，采用网络远程的方式举行。投资者可以登录"全景·路演天下"网 站（http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动。活动时 间为 2021 年 9 月 24 日（星期五）15：00-17：00。 届时，公司董事会秘书及证券事务代表将通过网络文字形式与投资者进行 交流与沟通，欢迎广大投资者积极参与。 特此公告。 爱威科技股份有 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1] - The company's revenue for the first half of 2021 was CNY 97,308,452.67, representing a year-on-year increase of 31.85%[19] - The net profit attributable to shareholders for the same period was CNY 12,615,548.51, a growth of 63.29% compared to the previous year[21] - The basic earnings per share rose to CNY 0.2474, reflecting a 63.30% increase year-on-year[20] - The company's total operating revenue for the first half of 2021 reached ¥97,308,452.67, an increase of 31.8% compared to ¥73,802,737.62 in the same period of 2020[144] - Net profit for the first half of 2021 was ¥12,615,548.51, representing a growth of 63.5% from ¥7,725,981.87 in the first half of 2020[145] Market Expansion and Strategy - The company expects a revenue growth of 25% for the second half of 2021, driven by new product launches and market expansion strategies[1] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[1] - The company is expanding its market presence in Asia, targeting a 30% increase in market share by the end of 2022[102] Research and Development - Research and development expenses increased by 30% compared to the previous year, focusing on machine vision technology and urine analysis products[1] - Research and development expenses accounted for 11.71% of revenue, a slight decrease of 0.37 percentage points from the previous year[20] - The company invested 11.39 million yuan in R&D, reflecting a 27.79% increase compared to the previous year[55] - The company has developed a fully automated urine, feces, and reproductive secretion testing series, utilizing machine vision technology to enhance testing speed and accuracy[32] - The company has developed a high-precision liquid path control technology that ensures accurate sample addition and stability in the counting pool, effectively solving cross-contamination and clogging issues[36] Operational Efficiency - The company experienced a lower growth rate in operating expenses compared to revenue growth, contributing to the increase in net profit[21] - The company is committed to reducing operational costs by 15% over the next year through efficiency improvements[102] Industry Trends - The in vitro diagnostics industry is experiencing rapid growth, particularly in emerging markets like China and India, with expected growth rates between 15% and 20%[27] - The integration of artificial intelligence in medical testing is identified as a key future direction for the industry[28] - The trend towards standardized and universal test results is expected to enhance diagnostic efficiency and reduce resource waste[28] Financial Position - The company's total assets increased by 77.56% to CNY 526,590,992.08, largely due to the net proceeds of CNY 20,957,980 raised from its IPO on the Sci-Tech Innovation Board[21] - The company's net assets grew by 93.87% to CNY 458,918,151.38 compared to the end of the previous year[19] - The company's total liabilities as of June 30, 2021, were RMB 67,672,840.70, up from RMB 59,851,139.88 at the end of 2020, marking an increase of about 30.4%[138] Shareholder Commitments - The company committed to a share lock-up period of 36 months for its controlling shareholder following its IPO[88] - The company will ensure compliance with the Company Law and Securities Law when shareholders decide to reduce their holdings post-lock-up[90] - The company has established measures to freeze remaining shares of any shareholder who violates the lock-up agreement[90] Compliance and Governance - The company has maintained compliance with environmental regulations, ensuring no significant pollution during production[85] - The company confirms that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[177] - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position and operating results accurately[179]